Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2016

Open Access 01-12-2016 | Review

Circadian clocks and breast cancer

Authors: Victoria Blakeman, Jack L. Williams, Qing-Jun Meng, Charles H. Streuli

Published in: Breast Cancer Research | Issue 1/2016

Login to get access

Abstract

Circadian clocks respond to environmental time cues to coordinate 24-hour oscillations in almost every tissue of the body. In the breast, circadian clocks regulate the rhythmic expression of numerous genes. Disrupted expression of circadian genes can alter breast biology and may promote cancer. Here we overview circadian mechanisms, and the connection between the molecular clock and breast biology. We describe how disruption of circadian genes contributes to cancer via multiple mechanisms, and link this to increased tumour risk in women who work irregular shift patterns. Understanding the influence of circadian rhythms on breast cancer could lead to more efficacious therapies, reformed public health policy and improved patient outcome.
Literature
1.
Chen S-T, et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241–6.CrossRefPubMed
2.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136:E359–86.CrossRef
3.
Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiol Camb Mass. 2005;16:254–8.CrossRef
4.
Gery S, Koeffler HP. Circadian rhythms and cancer. Cell Cycle Georget Tex. 2010;9:1097–103.CrossRef
5.
Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4:649–61.CrossRefPubMed
6.
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.CrossRefPubMed
7.
Cadenas C, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle Georget Tex. 2014;13:3282–91.CrossRef
8.
Filipski E, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690–7.CrossRefPubMed
9.
Hamilton T. Influence of environmental light and melatonin upon mammary tumour induction. Br J Surg. 1969;56:764–6.CrossRefPubMed
10.
Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001;63:647–76.CrossRefPubMed
11.
Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain Res. 2001;916:172–91.CrossRefPubMed
12.
Welsh DK, Logothetis DE, Meister M, Reppert SM. Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron. 1995;14:697–706.CrossRefPubMed
13.
Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20:293–307.CrossRefPubMed
14.
Reiter RJ, Gultekin F, Manchester LC, Tan D-X. Light pollution, melatonin suppression and cancer growth. J Pineal Res. 2006;40:357–8.CrossRefPubMed
15.
Pando MP, Morse D, Cermakian N, Sassone-Corsi P. Phenotypic rescue of a peripheral clock genetic defect via SCN hierarchical dominance. Cell. 2002;110:107–17.CrossRefPubMed
16.
17.
18.
Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350–61.CrossRefPubMed
19.
20.
21.
Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006;4:25–36.CrossRefPubMed
22.
Sahar S, Sassone-Corsi P. The epigenetic language of circadian clocks. Handb Exp Pharmacol. 2013;(217):29–44.
23.
Preitner N, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–60.CrossRefPubMed
24.
Reddy AB, Wong GKY, O’Neill J, Maywood ES, Hastings MH. Circadian clocks: neural and peripheral pacemakers that impact upon the cell division cycle. Mutat Res. 2005;574:76–91.CrossRefPubMed
25.
26.
Yi YW, et al. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013;4:984–94.CrossRefPubMedPubMedCentral
27.
Unsal-Kaçmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005;25:3109–16.CrossRefPubMedPubMedCentral
28.
Engelen E, et al. Mammalian TIMELESS is involved in period determination and DNA damage-dependent phase advancing of the circadian clock. PLoS One. 2013;8:e56623.CrossRefPubMedPubMedCentral
29.
30.
Yoo S-H, et al. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A. 2004;101:5339–46.CrossRefPubMedPubMedCentral
31.
Metz RP, Qu X, Laffin B, Earnest D, Porter WW. Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn Off Publ Am Assoc Anat. 2006;235:263–71.
32.
33.
34.
Sherratt MJ, McConnell J, Streuli CH. Raised mammographic density: causative mechanisms and biological consequences. Breast Cancer Res. 2016;18(1):45.
35.
36.
37.
Malik A, Kondratov RV, Jamasbi RJ, Geusz ME. Circadian clock genes are essential for normal adult neurogenesis, differentiation, and fate determination. PLoS One. 2015;10:e0139655.CrossRefPubMedPubMedCentral
38.
39.
Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41–50.CrossRefPubMed
40.
41.
Gery S, et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22:375–82.CrossRefPubMed
42.
Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342:9–18.CrossRefPubMed
43.
Shostak A, et al. MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation. Nat Commun. 2016;7:11807.CrossRefPubMedPubMedCentral
44.
Matsuo T, et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255–9.CrossRefPubMed
45.
Asher G, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134:317–28.CrossRefPubMed
46.
47.
48.
Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795–800.CrossRefPubMed
49.
Vaziri H, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–59.CrossRefPubMed
50.
Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324:654–7.CrossRefPubMed
51.
Nakahata Y, et al. The NAD + -dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008;134:329–40.CrossRefPubMedPubMedCentral
52.
Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144:5179–83.CrossRefPubMed
53.
54.
Um JH, et al. Activation of 5′-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem. 2007;282:20794–8.CrossRefPubMed
55.
Zhu Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat. 2008;107:421–5.CrossRefPubMed
56.
Rossetti S, Corlazzoli F, Gregorski A, Azmi NHA, Sacchi N. Identification of an estrogen-regulated circadian mechanism necessary for breast acinar morphogenesis. Cell Cycle Georget Tex. 2012;11:3691–700.CrossRef
57.
Akhtar N, Streuli CH. An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium. Nat Cell Biol. 2013;15:17–27.CrossRefPubMedPubMedCentral
58.
Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007;26:7916–20.CrossRefPubMed
59.
Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer. 2007;7:713–22.CrossRefPubMed
60.
Teboul M, Gréchez-Cassiau A, Guillaumond F, Delaunay F. How nuclear receptors tell time. J Appl Physiol Bethesda Md. 2009;1985(107):1965–71.
61.
Jiang W, et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016;371:314–25.CrossRefPubMed
62.
Climent J, et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3770–8.CrossRef
63.
Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557–62.CrossRefPubMed
64.
Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiol Camb Mass. 2001;12:74–7.CrossRef
65.
Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer Oxf Engl. 2005;1990(41):2023–32.CrossRef
66.
Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiol Camb Mass. 2006;17:108–11.CrossRef
67.
68.
Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.CrossRefPubMed
69.
70.
Menegaux F, et al. Night work and breast cancer: a population-based case–control study in France (the CECILE study). Int J Cancer. 2013;132:924–31.CrossRefPubMed
71.
Hurley S, et al. Light at night and breast cancer risk among California teachers. Epidemiol Camb Mass. 2014;25:697–706.CrossRef
72.
Van Dycke KCG, et al. Chronically Alternating Light Cycles Increase Breast Cancer Risk in Mice. Curr Biol CB. 2015;25:1932–7.CrossRefPubMed
73.
Schernhammer ES, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst. 2001;93:1563–8.CrossRefPubMed
74.
Brainard GC, Richardson BA, King TS, Reiter RJ. The influence of different light spectra on the suppression of pineal melatonin content in the Syrian hamster. Brain Res. 1984;294:333–9.CrossRefPubMed
75.
Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat. 2003;79:313–20.CrossRefPubMed
76.
77.
Dauchy RT, et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014;74:4099–110.CrossRefPubMedPubMedCentral
78.
Bracci M, et al. Rotating-shift nurses after a day off: peripheral clock gene expression, urinary melatonin, and serum 17-β-estradiol levels. Scand J Work Environ Health. 2014;40:295–304.CrossRefPubMed
79.
80.
Kochan DZ, et al. Circadian-disruption-induced gene expression changes in rodent mammary tissues. Oncoscience. 2016;3:58–70.PubMedPubMedCentral
81.
Gautherie M, Gros C. Circadian rhythm alteration of skin temperature in breast cancer. Chronobiologia. 1977;4:1–17.PubMed
82.
Mormont MC, Lévi F. Circadian-system alterations during cancer processes: a review. Int J Cancer J Int Cancer. 1997;70:241–7.CrossRef
83.
84.
Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014;64:207–18.CrossRefPubMed
Metadata
Title
Circadian clocks and breast cancer
Authors
Victoria Blakeman
Jack L. Williams
Qing-Jun Meng
Charles H. Streuli
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-016-0743-z

Other articles of this Issue 1/2016

Breast Cancer Research 1/2016 Go to the issue

Research article

Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer

Research article

Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study

Erratum

Erratum to: Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups

Review

Breast cancer brain metastases: biology and new clinical perspectives

Research article

The cell surface mucin podocalyxin regulates collective breast tumor budding

Research article

Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits